Related Experiment Video
Updated: Jul 13, 2026

Characterization of Molecular Mechanisms of In vivo UVR Induced Cataract
Published on: November 28, 2012
Risk factors for the development of cataract requiring surgery in uveitis associated with juvenile idiopathic
Karen M Sijssens1, Aniki Rothova, David A M C Van De Vijver
1FC Donders Institute of Ophthalmology, University Medical Center Utrecht, Utrecht, The Netherlands. K.Sijssens@umcutrecht.nl
Insights
Posterior synechiae are a key risk factor for early cataract surgery in children with juvenile idiopathic arthritis (JIA)-associated uveitis. Early methotrexate treatment may delay the need for cataract surgery in these patients.
Area of Science:
- Ophthalmology
- Pediatric Rheumatology
- Clinical Immunology
Background:
- Juvenile idiopathic arthritis (JIA) can lead to uveitis, a serious intraocular inflammation.
- Uveitis in JIA patients increases the risk of ocular complications, including cataract formation.
- Cataract surgery is often required in children with JIA-associated uveitis, impacting vision and quality of life.
Purpose of the Study:
- To determine the risk factors associated with the development of cataract requiring surgery in pediatric patients diagnosed with JIA-associated uveitis.
- To investigate clinical and ophthalmologic characteristics that predict the need for early cataract extraction in this cohort.
Main Methods:
- Retrospective cohort study analyzing data from 53 children with JIA-associated uveitis.
- Examined the interval between uveitis onset and first cataract extraction (U-CE interval).
- Evaluated the impact of clinical features (e.g., posterior synechia) and treatments (e.g., methotrexate, corticosteroids) on the U-CE interval.
Main Results:
- Children with posterior synechia at uveitis diagnosis had a significantly shorter U-CE interval (HR, 3.57).
- Treatment with methotrexate (MTX) was associated with a longer U-CE interval, suggesting a delay in cataract progression (HR, 0.29).
- No significant differences in U-CE interval were observed based on the initial manifestation of JIA or periocular corticosteroid use.
Conclusions:
- Posterior synechiae are identified as a significant risk factor for early cataract development requiring surgery in pediatric uveitis secondary to JIA.
- Early initiation of methotrexate treatment appears to be a protective factor, delaying the onset of visually significant cataracts by approximately 3.5 years.
Purpose:
To identify the possible risk factors for the development of cataract requiring surgery in children with juvenile idiopathic arthritis (JIA)-associated uveitis.
Design:
Retrospective cohort study.
Methods:
Data of 53 children with JIA-associated uveitis, of whom 27 had undergone cataract extraction (CE), were obtained. The main outcome measure, the interval between the onset of uveitis and the first CE (U-CE interval), was examined in relation to clinical and ophthalmologic characteristics and treatment strategies before CE.
Results:
A shorter U-CE interval was found for children with posterior synechia vs those without posterior synechia (hazard ratio [HR], 3.57; 95% confidence interval [CI], 1.33 to 10.00). No significant difference was found for children in whom the uveitis was the first manifestation of JIA vs those in whom arthritis was the first manifestation of JIA (HR, 1.59; 95% CI, 0.63 to 4.00) and children treated with periocular corticosteroid injections vs those not treated with periocular corticosteroid injections (HR, 3.23; 95% CI, 0.95 to 11.11). Children treated with methotrexate (MTX) had a longer U-CE interval than children not treated with MTX (HR, 0.29; 95% CI, 0.10 to 0.87).
Conclusions:
The risk factor for development of early cataract requiring surgery in children with JIA-associated uveitis is the presence of posterior synechia at the time of diagnosis of uveitis. However, early treatment with MTX is associated with a mean delay in the development of cataract requiring surgery of 3.5 years.
Related Concept Videos
Glaucoma: Overview
Photoreceptors and Visual Pathways
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
